Page last updated: 2024-10-24

butenafine and Leishmaniasis, Diffuse Cutaneous

butenafine has been researched along with Leishmaniasis, Diffuse Cutaneous in 1 studies

butenafine: studied on experimental dermatophytosis
butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.

Leishmaniasis, Diffuse Cutaneous: A form of LEISHMANIASIS, CUTANEOUS caused by Leishmania aethiopica in Ethiopia and Kenya, L. pifanoi in Venezuela, L. braziliensis in South America, and L. mexicana in Central America. This disease is characterized by massive dissemination of skin lesions without visceral involvement.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bezerra-Souza, A1
Yamamoto, ES1
Laurenti, MD1
Ribeiro, SP1
Passero, LF1

Other Studies

1 other study available for butenafine and Leishmaniasis, Diffuse Cutaneous

ArticleYear
The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Parasitology international, 2016, Volume: 65, Issue:6 Pt A

    Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Benzylamines; Drug Repositioning; Female; Leishman

2016